PT - JOURNAL ARTICLE AU - Mourton, S. M. AU - Sonoda, Y. AU - Abu-Rustum, N. R. AU - Bochner, B. H. AU - Barakat, R. R. AU - Chi, D. S. TI - Resection of recurrent cervical cancer after total pelvic exenteration AID - 10.1111/j.1525-1438.2007.00807.x DP - 2007 Jan 01 TA - International Journal of Gynecologic Cancer PG - 137--140 VI - 17 IP - 1 4099 - http://ijgc.bmj.com/content/17/1/137.short 4100 - http://ijgc.bmj.com/content/17/1/137.full SO - Int J Gynecol Cancer2007 Jan 01; 17 AB - The objective of this study was to describe the management of patients with recurrent cervical cancer after total pelvic exenteration (TPE). We reviewed the records of patients who underwent TPE for recurrent cervical cancer between June 1992 and December 2003 and subsequently developed recurrent disease. Thirty-seven patients underwent TPE during the study period, and 25 (68%) subsequently developed recurrence proven by radiographic and/or biopsy studies. Recurrence sites included pelvic (12), inguinal (5), retroperitoneal (5), hepatic (4), vulva (2), perineum (1), transposed ovary (1), and lung (1). The median time to recurrence was 7 months (range 2–73 months), with 92% (23/25) occurring within 2 years of TPE. Management of recurrence was known in 21 of 25 patients, which included chemotherapy (10), surgical resection (7), and no further treatment (4). Surgically resected recurrences were isolated to the groin (2), vulva (2), perineum (1), transposed ovary (1), and psoas muscle (1). The four patients who underwent ovarian, perineal, and vulvar resections succumbed to their disease in a median time of 13 months (range 2–21 months). Of the two patients with surgically resected groin recurrences, one is alive with disease 21 months after initial recurrence and the other is alive without evidence of disease 85 months later. One patient had an isolated 4-cm recurrence involving the psoas muscle and the femoral nerve and is without the evidence of disease 9 months later. Resection of isolated recurrences after TPE is a reasonable option in selected patients, particularly in those with solitary inguinal metastases